Compared with BAF wild‐type NSCLC, patients with BAF‐mutated NSCLC (n = 335) had a significantly shorter median OS from the time of advanced disease diagnosis (19.3 vs. 25 mos; HR 0.82; 95% confidence interval [CI] 0.71–0.96; p = 0.01), which was driven mainly by SMARCA4‐mutated cases (25 months vs. 15.6 months for SMARCA4 wild‐type and mutated, respectively) [16]. This evidence concerns the gene SMARCA4 and non-small cell lung carcinoma.